Get the Stockscreener App
8.9445
2.85%
-0.1855
Sutro Biopharma Inc stock is traded at $8.9445, with a volume of 46,827.
It is down -2.85% in the last 24 hours and down -0.34% over the past month.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
See More
Previous Close:
$9.13
Open:
$9.01
24h Volume:
46,827
Relative Volume:
0.44
Market Cap:
$75.57M
Revenue:
$153.73M
Net Income/Loss:
$-106.79M
P/E Ratio:
-5.025
EPS:
-1.78
Net Cash Flow:
$-115.93M
1W Performance:
-9.58%
1M Performance:
-0.34%
6M Performance:
+11.74%
1Y Performance:
-52.05%
1-Day Range:
$8.66
$9.245
1-Week Range:
$8.66
$10.10
52-Week Range:
$5.231
$21.50
Sutro Biopharma Inc Stock (STRO) Company Profile
Name
Sutro Biopharma Inc
Sector
Industry
Phone
650-392-8412
Address
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
8.87 | 77.78M | 153.73M | -106.79M | -115.93M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.94 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
747.67 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.15 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.83 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
163.74 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-17-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Downgrade | Wedbush | Outperform → Neutral |
| May-08-24 | Initiated | BofA Securities | Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-06-23 | Initiated | Oppenheimer | Outperform |
| Mar-21-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jun-18-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Jul-16-20 | Initiated | Wells Fargo | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Oct-07-19 | Initiated | BTIG Research | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Apr-29-19 | Initiated | H.C. Wainwright | Buy |
| Oct-22-18 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
| Oct-22-18 | Initiated | Wedbush | Outperform |
View All
Sutro Biopharma Inc Stock (STRO) Latest News
Sutro Biopharma regains Nasdaq compliance after meeting minimum bid price - Investing.com Canada
Sutro Biopharma regains Nasdaq compliance after meeting minimum bid price By Investing.com - Investing.com South Africa
Sutro Biopharma Regains Nasdaq Listing Compliance - TipRanks
Sutro Biopharma regains Nasdaq compliance after reverse stock split By Investing.com - Investing.com South Africa
Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - The Manila Times
Sutro Biopharma Regains Nasdaq Compliance Following Reverse Stock Split - Quiver Quantitative
CEO Chung Acquires 1,606 Of Sutro Biopharma Inc [STRO] - TradingView — Track All Markets
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates - MSN
Net margin % of Sutro Biopharma, Inc. – FWB:S090 - TradingView — Track All Markets
Sutro Biopharma Earnings Notes - Trefis
Wells Fargo Reaffirms Their Hold Rating on Sutro Biopharma (STRO) - The Globe and Mail
RBF Capital LLC Purchases New Position in Sutro Biopharma, Inc. $STRO - MarketBeat
Velan Capital Investment Management LP Acquires 2,030,000 Shares of Sutro Biopharma, Inc. $STRO - MarketBeat
Sutro Biopharma (STRO) price target increased by 1,325.54% to 39.05 - MSN
Check out Sutro Biopharma's stock price (S090-FF) in real time - CNBC
Exit Recap: Will Sutro Biopharma Inc stock benefit from automationTrade Analysis Report & Low Risk Growth Stock Ideas - moha.gov.vn
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Sutro Biopharma (NASDAQ:STRO) Shares Gap DownWhat's Next? - MarketBeat
Will Sutro Biopharma Inc. (S09) stock sustain bullish trend into 20252025 Big Picture & AI Forecasted Stock Moves - Newser
Can Sutro Biopharma Inc. stock sustain institutional interestJuly 2025 Institutional & Smart Investment Allocation Tips - Newser
Is Sutro Biopharma Inc. (S09) stock a top dividend aristocrat candidatePrice Action & Weekly Market Pulse Alerts - Newser
Sutro Biopharma (NASDAQ:STRO) Shares Gap UpWhat's Next? - MarketBeat
Is Sutro Biopharma Inc. (S09) stock attractive for growth fundsPortfolio Risk Report & Weekly Watchlist of Top Performers - Newser
Sutro Biopharma doses first patients in phase 1 trial of STRO-004 - Investing.com Canada
Sutro Biopharma (NASDAQ:STRO) Receives "Neutral" Rating from Wedbush - MarketBeat
Sutro Biopharma Announces Reverse Stock Split - TipRanks
Sutro Biopharma (NASDAQ:STRO) Given Neutral Rating at Wedbush - Defense World
Sutro Biopharma Initiates Dosing in Phase 1 TF-Expressing Cancer Study - MarketScreener
Sutro Biopharma (STRO) Initiates Phase 1 Trial of STRO-004 for S - GuruFocus
Sutro Biopharma announces first cohort of patients dosed in phase 1 trial of Stro-004 - marketscreener.com
Are Smart Investors Making the Right Decision? Sutro Biopharma Inc (STRO) - setenews.com
Sutro Biopharma doses first patients in phase 1 trial of STRO-004 By Investing.com - Investing.com South Africa
Sutro Biopharma, Inc. Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in Tissue Factor - marketscreener.com
What MACD trends signal for Sutro Biopharma Inc. (S09) stockWeekly Market Outlook & Low Volatility Stock Recommendations - Newser
Will Sutro Biopharma Inc. stock outperform value stocks2025 Market Overview & AI Enhanced Execution Alerts - Newser
Sutro Biopharma falls as it announces 1-for-10 reverse stock split - MSN
Why Sutro Biopharma Inc. stock is popular among millennials2025 Breakouts & Breakdowns & Daily Profit Maximizing Trade Tips - Newser
How Sutro Biopharma Inc. stock reacts to inflationary pressures2025 Big Picture & High Return Trade Opportunity Guides - Newser
What earnings margins imply for Sutro Biopharma Inc. (S09) stockEarnings Trend Report & Daily Technical Stock Forecast Reports - Newser
Sutro Biopharma announces 1-for-10 reverse stock split By Investing.com - Investing.com Australia
Sutro Biopharma stock falls after announcing 1-for-10 reverse split - Investing.com Canada
Sutro Biopharma Sets 1-for-10 Reverse Stock Split - Nasdaq
Sutro Biopharma Announces 1-for-10 Reverse Stock Split - The Manila Times
Sutro Biopharma announces 1-for-10 reverse stock split - marketscreener.com
Sutro Biopharma Inc Stock (STRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):